| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
This compound does not have a specific biological target. The DBCO group participates in strain-promoted azide-alkyne cycloaddition (SPAAC), a copper-free click chemistry reaction that allows for highly specific and efficient labeling of azide-modified biomolecules in live physiological environments without the need for a toxic copper catalyst. The Cy3 fluorophore provides bright, stable fluorescence for detection and imaging.
|
|---|---|
| ln Vitro |
Compared to TAMRA and the majority of other widely used fluorescent dyes, DBCO-Cy3 has less background. A 532 nm or 555 nm laser line can be used to excite DBCO-Cy3, which can then be attached to antibodies, peptides, and proteins. A TRITC filter bank can be used to observe the resultant signal.
DBCO-Cy3 is not a bioactive compound but a fluorescent labeling reagent. When used in pre-targeted imaging, an azide-modified targeting molecule (e.g., an antibody or nanoparticle) is first administered and allowed to accumulate at the site of interest. Subsequently, the DBCO-Cy3 probe is introduced, which rapidly and specifically reacts with the azide-tagged molecule via SPAAC, enabling fluorescent visualization of the target tissue. This method significantly enhances signal-to-background ratio. |
| ln Vivo |
For in vivo imaging, pre-targeting approaches using DBCO-Cy3 have been developed. In mouse models, the pre-targeting interval (time between administration of azide-tagged molecule and DBCO-Cy3) is typically 24-72 hours to allow clearance of unbound azide-tagged molecules from circulation. DBCO-Cy3 is then administered intravenously (tail vein injection) and imaging is performed at 1, 4, 24, and 48 hours post-injection. The recommended dosage is 1-5 mg/kg in PBS, saline, or DMSO/saline mixture as vehicle.
|
| Enzyme Assay |
For in vitro SPAAC labeling: Prepare azide-modified biomolecules in PBS (pH 7.4). Add DBCO-Cy3 at a 2-10 fold molar excess relative to azide concentration. Incubate at room temperature for 30 minutes to 2 hours. The reaction does not require a copper catalyst. Monitor conjugation efficiency by SDS-PAGE with fluorescence detection (excitation at 550 nm, emission at 570 nm).
|
| Cell Assay |
For cell labeling: Fix and permeabilize cells after appropriate treatment. Add DBCO-Cy3 at 1 uM concentration and incubate for 30-60 minutes at room temperature. Wash cells to remove unreacted dye. Perform confocal microscopy using appropriate filter sets for Cy3.
|
| Animal Protocol |
For in vivo imaging in mice: Administer azide-modified targeting antibody or nanoparticle intravenously. Allow 24-72 hours for accumulation at the target site and clearance from circulation. Inject DBCO-Cy3 (1-5 mg/kg) via tail vein. Perform fluorescence imaging at various time points using an imaging system equipped with Cy3 filter sets. For ex vivo imaging, collect tissues (tumor, liver, spleen, kidney) and image immediately.
|
| ADME/Pharmacokinetics |
DBCO-Cy3 is administered intravenously via tail vein injection at a recommended starting dose of 1-5 mg/kg in vehicle (PBS, saline, or DMSO/saline mixture). The final DMSO concentration should be kept non-toxic (<10%). Imaging is performed at 1, 4, 24, and 48 hours post-injection. For in vitro imaging, cells can be imaged immediately after labeling. The fluorescence of Cy3 is largely insensitive to pH in the physiological range (pH 4-10), making it suitable for various biological environments. The photostability of DBCO-Cy3 is reported to be good, but should be evaluated for specific demanding applications.
|
| Toxicity/Toxicokinetics |
No formal pharmacokinetic studies are available for DBCO-Cy3 in isolation. The small molecular size of the probe (molecular weight approximately 800-900 g/mol) allows for rapid distribution and clearance. In pre-targeted imaging approaches, the majority of unbound probe is cleared from circulation within 24 hours, allowing for high signal-to-background ratios at later imaging time points.
|
| Additional Infomation |
No specific toxicity data is available for DBCO-Cy3. The DBCO group is reactive but generally biocompatible at the concentrations used for imaging. The Cy3 dye has a well-established safety profile for in vivo use in research settings. Standard laboratory safety practices should be followed when handling.
|
| Molecular Formula |
C50H54N4O11S3
|
|---|---|
| Molecular Weight |
983.178969860077
|
| Exact Mass |
982.295
|
| CAS # |
1782950-79-1
|
| PubChem CID |
146026283
|
| Appearance |
Purple to purplish red solid powder
|
| LogP |
5.1
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
68
|
| Complexity |
2350
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C=CC2=C(C=1)C(C)(C)/C(=C\C=C\C1C(C)(C)C3C=C(C=CC=3[N+]=1CCCS(=O)(=O)O)S(=O)(=O)[O-])/N2CCCCCC(NCCC(N1C2C=CC=CC=2C#CC2C=CC=CC=2C1)=O)=O)(=O)(=O)O
|
| InChi Key |
ALLGTQOHAQKUOH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C50H54N4O11S3/c1-49(2)40-32-38(67(60,61)62)23-25-43(40)52(45(49)18-12-19-46-50(3,4)41-33-39(68(63,64)65)24-26-44(41)53(46)30-13-31-66(57,58)59)29-11-5-6-20-47(55)51-28-27-48(56)54-34-37-16-8-7-14-35(37)21-22-36-15-9-10-17-42(36)54/h7-10,12,14-19,23-26,32-33H,5-6,11,13,20,27-31,34H2,1-4H3,(H3-,51,55,57,58,59,60,61,62,63,64,65)
|
| Chemical Name |
3-[2-[(E,3E)-3-[1-[6-[[3-(2-azatricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaen-10-yn-2-yl)-3-oxopropyl]amino]-6-oxohexyl]-3,3-dimethyl-5-sulfoindol-2-ylidene]prop-1-enyl]-3,3-dimethyl-5-sulfoindol-1-ium-1-yl]propane-1-sulfonate
|
| Synonyms |
DBCOCy3; DBCO Cy3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~63.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0171 mL | 5.0855 mL | 10.1711 mL | |
| 5 mM | 0.2034 mL | 1.0171 mL | 2.0342 mL | |
| 10 mM | 0.1017 mL | 0.5086 mL | 1.0171 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
